[Mechanisms of action of repaglinide at a cellular level].
In type 2 diabetic patients, the important post-prandial hyperglycemic peak combined with the defective insulin secretion emphasizes the need for restoring a physiological insulin profile during meals, characterized by insulinemia peaking within 1 hour and returning to basal levels within 4 hours. During type 1 diabetes mellitus, short acting insulin analogs aim at counteracting on post-prandial hyperglycemic peak. During type 2 diabetes mellitus, repaglinide is the first fast-acting oral antidiabetic drug able to stimulate endogenous insulin secretion during meal by mimicking physiological insulin secretion pattern.
Thomsen
M K
MK
D002219:Carbamates / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007444:Inulin / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*
D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; C072379:repaglinide; D007444:Inulin